The groundbreaking success of Sildenafil undeniably reshaped the pharmaceutical landscape, but betting in companies strongly reliant on unbranded versions presents a complex picture. Despite early returns were significant, the expiration of patents and the emergence of discounted alternatives have diminished the customer base. Consequently, a thoro